Lung Cancer | Specialty

Daiichi Sankyo, Gustave Roussy Research Partnership Holds Promise for NSCLC, Breast Cancer Paradigms

September 8th 2020

A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.

Dr. Konduri on Sequencing Challenges in ALK+ NSCLC

September 8th 2020

Kartik Konduri, MD, discusses remaining sequencing challenges in ALK-positive non–small cell lung cancer.

Expanded Lung Cancer Screening Criteria Would Boost Survival Outcomes

September 5th 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

September 5th 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

FDA Approves Pralsetinib for Metastatic RET+ NSCLC

September 5th 2020

The FDA has approved pralsetinib for the treatment of patients with metastatic, RET fusion–positive non-small cell lung cancer.

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

September 3rd 2020

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer.

Dr. Pennell on Remaining Challenges in NSCLC

September 3rd 2020

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Capmatinib Continues to Show Significant Antitumor Activity in METex14+ NSCLC

September 3rd 2020

Capmatinib continued to elicit a significant, durable responses in patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon14 skipping mutation.

Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC

September 2nd 2020

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Selpercatinib Demonstrates Durable Efficacy and Intracranial Activity in RET+ NSCLC

September 2nd 2020

The RET inhibitor selpercatinib was shown to have durable efficacy with mostly low-grade adverse effects in patients with RET fusion–positive non–small-cell lung cancer.

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

September 1st 2020

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Updates on I/O Therapy for Non-Driver mNSCLC

September 1st 2020

EGFR Exon 20 Mutations in NSCLC

September 1st 2020

KRAS-Mutant NSCLC

September 1st 2020

HER2 Targeted Therapy for Treatment of NSCLC

September 1st 2020

MET Exon 14 Mutations in mNSCLC

September 1st 2020

RET Fusion+ mNSCLC

September 1st 2020

Dr. Horn on the Role of Mobocertinib in NSCLC

August 28th 2020

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Dr. Pennell on the Evolution of Targeted Treatment in NSCLC

August 27th 2020

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

August 27th 2020

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.